Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients.
Saved in:
| Title: | Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients. |
|---|---|
| Authors: | Torasawa, Masahiro1,2 (AUTHOR), Yoshida, Tatsuya1,3 (AUTHOR) tatyoshi@ncc.go.jp, Takeyasu, Yuki1 (AUTHOR), Shimoda, Yukiko1 (AUTHOR), Tateishi, Akiko1 (AUTHOR), Matsumoto, Yuji1 (AUTHOR), Masuda, Ken1 (AUTHOR), Shinno, Yuki1 (AUTHOR), Okuma, Yusuke1 (AUTHOR), Goto, Yasushi1 (AUTHOR), Horinouchi, Hidehito1 (AUTHOR), Yamamoto, Noboru1,3 (AUTHOR), Takahashi, Kazuhisa2 (AUTHOR), Ohe, Yuichiro1 (AUTHOR) |
| Source: | Cancer Medicine. Jun2023, Vol. 12 Issue 11, p12388-12401. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
